Drug intelligence / Profile preview

ENV1305

Development stage: Preclinical
Lead developer: Envisia Therapeutics
Modality: Small Molecules
Administration: Intravitreal

Overview

ENV1305 is an investigational drug developed for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It acts as an anti-VEGF-A therapy, aiming to inhibit vascular endothelial growth factor A (VEGF-A), a key driver of abnormal blood vessel growth and leakage in nAMD. The drug is being developed by Envisia Therapeutics and is currently in preclinical development. Its mechanism involves antagonism of VEGF-A, thereby reducing pathological angiogenesis and vascular permeability associated with wet AMD[1][2][4].

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on ENV1305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENV1305.

Explore the full profile